Mankind Pharma Limited (MANKIND) — Annual Report

📢 Key Event
Mankind Pharma announces 35th AGM scheduled for August 4, 2026, via video conferencing with e-voting from August 1-3, 2026.

🔄 What Changed
Reappointment of Satish Kumar Sharma as Whole Time Director; ratification of cost auditor remuneration of ₹25.50 lakhs; disclosure of FY2026 financial performance including ₹14,278 crores revenue and ₹1,938 crores PAT.

🔮 What's Next
The company emphasized expansion in chronic therapies, digital transformation, and ESG initiatives, targeting 50% chronic therapy share by medium-term and 100% renewable energy by FY2030.

💡 Investor Takeaway
The AGM will focus on director reappointments, auditor ratification, and reviewing FY2026 performance, with strategic emphasis on chronic therapy growth and digital innovation.

Mankind Pharma Limited announced its 35th Annual General Meeting (AGM) scheduled for August 4, 2026, via video conferencing, with e-voting open from August 1 to 3, 2026. The filing includes details on shareholder participation, voting procedures, and financial disclosures for subsidiaries and associates. Key financial highlights include revenue of ₹14,278 crores, PAT of ₹1,938 crores, and EBITDA of ₹3,629 crores for FY2026, reflecting 17% YoY growth. The company reappointed Satish Kumar Sharma as Whole Time Director and recommended ratification of M/s M.K. Kulshrestha & Associates as Cost Auditors for ₹25.50 lakhs. Strategic focus areas include expansion in chronic therapies, digital transformation, and ESG initiatives, with 41% sustainable sourcing and 100% EPR compliance. Risks include regulatory, supply chain, and foreign exchange volatility.

📄 View Original Announcement (PDF)

📊 Stock Analysis — MANKIND ✨ Ask AI About This